Madrigal seeks accelerated approval for experimental NASH treatment a week after Intercept rejection
30 Jun 2023
Phase 3Accelerated ApprovalClinical ResultNDA
Madrigal Pharmaceuticals kicked off the regulatory review process for its experimental NASH treatment as it pursues the first FDA approval to treat the debilitating and sometimes fatal liver disease for which no other therapies exist.
Madrigal announced Friday that it began a rolling submission for accelerated approval of resmetirom as a treatment for NASH with liver fibrosis, based on data showing that the thyroid hormone beta-receptor agonist met both primary surrogate endpoints in a Phase III trial. The company said it submitted the majority of its NDA, and it plans to file the remaining components in July.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.